Ghost Tree Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Ghost Tree Capital’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250,000	Closed	-$1.21M	–	79
2023 Q3	$1.21M	Hold	250,000	–	–	0.4%	58
2023 Q2	$1.71M	Buy	250,000 +100,000	+67%	+$777K	0.56%	40
2023 Q1	$1.09M	Buy	150,000 +60,000	+67%	+$641K	0.32%	49
2022 Q4	$1.16M	Sell	90,000 -110,000	-55%	-$1.44M	0.49%	30
2022 Q3	$2.83M	Buy	200,000 +50,000	+33%	+$657K	0.79%	32
2022 Q2	$1.85M	Hold	150,000	–	–	0.96%	27
2022 Q1	$2.55M	Sell	150,000 -50,000	-25%	-$958K	0.55%	30
2021 Q4	$4.83M	Buy	+200,000	New	+$5.02M	1.73%	21

Other funds holding WHWK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ghost Tree Capital's WHWK Position: Q4 2023 in Review

Ghost Tree Capital sold out of Whitehawk Therapeutics (WHWK) in Q4 2023, closing a stake of 250,000 shares — an estimated $1.21M sold.

Ghost Tree Capital first reported a position in WHWK in Q4 2021 and held it in 8 quarters. The position peaked at $4.83M in Q4 2021. 65 funds tracked by Wall St. Rank hold WHWK as of Q4 2023.

Ghost Tree Capital reported no remaining Whitehawk Therapeutics position as of Q4 2023 after selling out during the quarter.
Ghost Tree Capital sold 250,000 Whitehawk Therapeutics shares in Q4 2023, an estimated $1.21M.
Ghost Tree Capital first reported a position in Whitehawk Therapeutics in Q4 2021 and held it in 8 quarters.
Ghost Tree Capital's Whitehawk Therapeutics position peaked at $4.83M in Q4 2021.
65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.